

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/509,940
Filing Date	June 3, 2005
First Named Inventor	Peter K. LAW
Art Unit	1633
Examiner Name	Ileana Popa
Attorney Docket Number	LAW.020.0002.PC

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	SUZUKI, K. et al. Cell Transplantation for the Treatment of Acute Myocardial Infarction Using Vascular Endothelial Growth Factor-Expressing Skeletal Myoblasts. Circulation. 18 September 2001, Vol.104, [suppl 1]. Pages I-207-I-212	
	2	POWELL, C. et al. Tissue-Engineered Human Bioartificial Muscles Expressing a Foreign Recombinant Protein for Gene Therapy, Human Gene Therapy. 01 March 1999, Vol. 10, No.4, pages 565-577	
	3	LAWRENCE F. BROWN et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) by Epidermal Keratinocytes during Wound Healing", J. Exp. Med., November 1992, pp.1375-1379. Vol. 176	
	4	PETER LAW et al., "Myoblast transfer as a platform technology of gene therapy", Gene Therapy and Molecular Biology, March 1998, pp.345-363, Vol.1	
	5	PETER K. LAW, "The Regenerative Heart", Business Briefing: Pharmatech 2002, p.65-71	
	6	LAW, P. et al., "World's First Human Myoblast Transfer into the Heart", Frontiers in Physiology, August 16-19, 2000, Joint Meeting, Stockholm, Sweden	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.